Latest:
Dr Siegel on the Current and Future Role of Mezigdomide in Multiple Myeloma
David Samuel Dicapua Siegel, MD, discusses the current and future role for mezigdomide in the multiple myeloma treatment paradigm.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
David Maloney, MD, PhD
Latest:
Dr. Maloney on Targets for CAR T-Cell Therapy
David Maloney, MD, PhD, professor of medicine, Division of Oncology, University of Washington, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses the success and challenges of chimeric antigen recptor (CAR) T-cell therapy in hematologic malignancies.
David Morris, MD, FACS
Latest:
Dr Morris on Active Surveillance in Low- and Intermediate-Risk Patients With Prostate Cancer
David Morris, MD, FACS, discusses the best practices for active surveillance in low- and intermediate-risk patients with prostate cancer, highlighting factors to look for in patients undergoing active surveillance that may point to the need for further treatment.
David Mutch, MD
Latest:
Dr. Mutch on Frontline Treatment in Endometrial Cancer
David Mutch, MD, Ira C. and Judith Gall professor, vice chair of obstetrics and gynecology, chief, Division of Gynecologic Oncology, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses frontline treatment for patients with endometrial cancer.
David P. Mason, MD
Latest:
Dr. Mason on Progress Made in Resectable Stage III Lung Cancer
David P. Mason, MD, chief of thoracic surgery and lung transplantation, Baylor Scott & White Health, chief of lung transplantation, head of the Department of Thoracic Surgery, Baylor University Medical Center, discusses the progress that has been made in resectable stage III lung cancer.
David Parker, PhD
Latest:
CMS Decision Helps Unlock the Potential of Next-Generation Testing
Provisions to a final national coverage determination that expanded coverage for next-generation sequencing tests have implications for any NGS-based cancer test provided to Medicare beneficiaries and will inevitably influence
the coverage thinking of commercial payers.
David Planchard, MD, PhD
Latest:
Dr. Planchard on Dabrafenib/Trametinib Combo in Advanced NSCLC
David Planchard, MD, PhD, Department of Medical Oncology, Thoracic Unit, Institut Gustave Roussy, discusses a phase II trial examining the combination of dabrafenib and trametinib in pretreated patients with BRAF V600E-mutant advanced non–small cell lung cancer (NSCLC).